Screening for pre-eclampsia using serum placental growth factor and endoglin with Down's syndrome Quadruple test markers

Journal of Medical Screening

Volumn 19, Issue 2, 2012, Pages 60-67

  Wald, Nicholas J ^a   Bestwick, Jonathan P ^a   George, Lynne M ^a   Wu, Tiesheng ^a   Morris, Joan K ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR;

ARTICLE; BLOOD; CASE CONTROL STUDY; DOWN SYNDROME; FEMALE; HUMAN; PREECLAMPSIA; PREGNANCY;

ANTIGENS, CD; CASE-CONTROL STUDIES; DOWN SYNDROME; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTERS; RECEPTORS, CELL SURFACE;

EID: 84864371722     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2012.011114     Document Type: Article

References (23)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99 (Pubitemid 40311367)
2. Wald NJ, Morris JK, Ibison J, Wu T, George LM. Screening in early pregnancy for pre-eclampsia using Down syndrome Quadruple test markers. Prenat Diag 2006;26:559-64 (Pubitemid 43989192)
3. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in pre-eclampsia. N Engl J Med 2006;355:992-1005 (Pubitemid 44343543)
4. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of pre-eclampsia. N Engl J Med 2004;350:672-83 (Pubitemid 38364626)
5. Lambert-Messerlian GM, Palomaki GE, Neveux LM, et al. Early onset pre-eclampsia and second trimester serum markers. Prenat Diagn 2009;29:1109-17
6. Morris JK, Wald NJ. Graphical presentation of distributions of risk in screening. J Med Screen 2005;12:155-60 (Pubitemid 41337149)
7. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330: 549-50
8. Dersimmonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88 (Pubitemid 17189972)
9. Su YN, Lee CN, Cheng WF, et al. Decreased maternal serum placenta growth factor in early second trimester and pre-eclampsia. Obstet Gynecol 2001;97:898-904 (Pubitemid 32522485)
10. Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM. Effective prediction of pre-eclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008;111;1403-9
11. Polliotti BM, Fry AG, Saller DN, et al. Second trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset pre-eclampsia. Obstet Gynecol 2003;101:1266-74 (Pubitemid 36694354)
12. Unal ER, Robinson CJ, Johnson DD, Chang EY. Second-trimester angiogenic factors as biomarkers for future-onset pre-eclampsia. Am J Obstet Gynecol 2007;197:p211.e1-e4
13. Tjoa MM, van Vugt JM, Mulders MA, Schutgens RB, Oudejans CB, van Wijk IJ. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001;98:600-7 (Pubitemid 32907454)
14. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical pre-eclampsia. Am J Obstet Gynecol 2001;184:1267-72 (Pubitemid 32434285)
15. Bersinger NA, Odegard RA. Second and third-trimester serum levels of placental proteins in pre-eclampsia and small-forgestational- age pregnancies. Acta Obstet Gynecol Scan 2004; 83:37-45 (Pubitemid 38121729)
16. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177-82 (Pubitemid 36135616)
17. Sibai BM, Koch MA, Freire S, et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous pre-eclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent pre-eclampsia? Am J Obstet Gynecol 2008;199: 268.e1-e9
18. Fang M, He Y, Li H,Wu M, Shi X, Du H. Alterations of serum and placental endoglin in pre-eclampsia. J Int Med Res 2010;38:43-51
19. Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing pre-eclampsia. Hypertension 2007;50:137-42 (Pubitemid 46986022)
20. Robinson CJ, Johnson DD. Soluble endoglin as a second-trimester marker for pre-eclampsia. Am J Obstet Gynecol. 2007;197:174.e1-e5
21. Lim JH, Kim SY, Park SY, et al. Soluble endoglin and transforming growth factor-b1 in women who subsequently developed pre-eclampsia. Prenat Diagn 2009;29:471-6
22. Bujold E, Roberge S, Lacasse Y, et al. Prevention of pre-eclampsia and intrauterine growth restriction with aspirin started in early pregnancy. Obstet Gynecol 2010;116(2 Pt 1):402-14
23. Vadillo-Ortega F, Perichart-Perera O, Espino S, et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ 2011;342: d2901